Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Capsular group B Neisseria meningitidis is one of the leading causes of death in developed countries. A new vaccine (4CMenB) has recently been developed which was found to have an acceptable safety profile in clinical studies and to be immunogenic. This review examines the evidence supporting the licensure of the 4CMenB vaccine and discusses recommendations for its use.

Original publication




Journal article


J Infect

Publication Date



71 Suppl 1


S15 - S20


Capsular group B Neisseria meningitidis, Capsular group C Neisseria meningitidis, Children, Immunogenicity, Infant, Reactogenicity, Vaccine, Adolescent, Adult, Child, Child, Preschool, Humans, Infant, Infant, Newborn, Meningococcal Infections, Meningococcal Vaccines, Middle Aged, Neisseria meningitidis, Serogroup B, Young Adult